The compounds found in cannabis plants may have developed as a mechanism to deter animals from eating the leaves, also to protect the plant from microorganisms and UV radiation.
The earliest proven human use of cannabis as a psychoactive agent was about 2,500 years ago, in the Pamir Plateau of what is now the far western edge of modern China. At that time, it was burned in wooden braziers (fire pits), probably as part of a funeral ritual. Cannabis was used for other purposes, such as food and hemp weaving, for a much longer time, dating back 5,000 to 10,000 years in other parts of China and Japan.
After this ancient starting point in central Asia, cannabis was commonly used as a psychoactive agent in India, the Middle East, and China. After about 1500, cannabis use spread to eastern Africa, where it was incorporated into existing African smoking cultures. African innovation in smoking cannabis helped create the now-global practice. The Spanish Empire brought cannabis to Mexico in the 1500s as a fiber crop, but local people started using it as an intoxicant soon afterwards, especially soldiers, prisoners, and indigenous people. Europeans prior to the 20th century mainly used cannabis products for hemp rather than for intoxication.
Reports from ancient times about the effects of the drug are comparable to modern accounts: sporadic use could be enjoyable or reportedly helpful for various ailments, but excessive use could harm individual health or cause community problems.
Various prohibition measures began in the 1800s, bolstered by European views that cannabis was exotic and dangerous. American prohibition campaigns began in the 1920s, culminating in the Marihuana Tax Act of 1937. The issue was entangled with racism and xenophobia, since cannabis use at the time was linked, from the perspectives of many in the White majority, to Mexican immigrants and African American jazz culture. The term “marijuana” was not invented by prohibitionists, but prohibitionist rhetoric used the Spanish-sounding word to make the plant seem foreign or threatening. The government claimed that “marihuana” (as they spelled it at the time) was a dangerous, foreign drug that caused insanity and violent crime.
While cannabis was illegal in the U.S. through most of the 1900s, mass enforcement escalated especially in the 1960s, then even further in the 1990s. In the U.S. alone, hundreds of thousands of people were arrested simply for cannabis possession, thousands of whom receiving prison sentences. Tens of billions of dollars were spent on policing, courts, and incarceration. This criminalization process almost certainly caused much more harm to individuals and to society than occasional cannabis use itself.
Cannabis was finally legalized in Canada in 2018. I support legalization. But legalization should not require us to pretend that cannabis is harmless.
Cannabis use is common, particularly in young adults. Usage among older generations is much lower but has gradually increased over the past decades. My rough summary of various sources of data is that among young adults, about 40% have used cannabis in the past year, about 10% on a daily or almost-daily basis. There is a concerning prevalence of use in children, especially problematic since cannabis likely carries particular risks to the still-developing adolescent brain. Among teenagers in grades 7-12, about 20% have used in the past year, 4% using almost daily.
Fortunately, legalization of cannabis does not appear to have caused a surge in adolescent use. But there are other concerns: higher-potency products, frequent use among a minority, commercialization, retail saturation, normalization, and the cultural message that cannabis is just another lifestyle accessory.
Why people like it
People commonly describe relaxation, laughter, softening of tension, food tasting better, time seeming slower or more spacious, and ordinary details feeling newly vivid. Many also describe a temporary reduction in self-consciousness, with conversation feeling easier or more playful. Cannabis has long been associated with enhanced music experiences such as altered auditory perception, greater sensitivity, and increased absorption in rhythm, tone, and mood.
There are also many anecdotes from creative people. There have been public claims from musicians and artists such as Louis Armstrong and Brian Wilson, and from Steve Jobs, that cannabis relaxed them or loosened associative thinking. Carl Sagan’s famous anonymous essay is the clearest scientist’s version of the same claim, that it may heighten appreciation, novelty, association, and perspective in some people.
Dosing and potency
One difficulty with cannabis is that many people don’t know exactly how much they are taking.
THC (tetrahydrocannabinol) is the main psychoactive component of cannabis. A “standard unit” of THC is 5 mg. This is very roughly analogous to a “standard drink” in the alcohol use literature (that is, one beer or one glass of wine, etc.). But it’s hard to know, if smoking or vaping cannabis, exactly how many of these standard units one is ingesting. Homemade edibles may be especially unpredictable in terms of THC quantity. Also, this is not a declaration that one standard unit of THC is safe for everyone or that it is a recommended serving: some people may be much more strongly affected by the same dose.
I often think of very rough comparisons with familiar prescription drugs in psychiatry; THC has a similar potency as diazepam (Valium): a single 5 mg tablet of Valium is a low dose, with very noticeable but mild effects for most people. 10 mg THC is a full recreational dose for many users, 20 mg a large dose, and up to 100 mg is an extreme dose. People have varying degrees of sensitivity or tolerance to these doses, both to THC and to diazepam, depending on past experience, individual variation, and other factors. I am not saying that diazepam and THC are otherwise similar—except in the sense that the magnitude of their subjective effects are roughly comparable at similar doses; also they have some curious similarities in metabolism, whereby there is a steep peak shortly after use, a rapid drop-off over several hours, but then a lengthy “tail” effect where lower levels can persist for days. I use this comparison with diazepam as a type of very approximate “anchor” to keep in mind, because in general cannabis ingestion tends to lack such clear dosage anchors. Many people have no idea how much they are using.
Regular users of cannabis often consume high amounts of THC, often 50-100 mg daily.
In the 1960s, cannabis potency was often about 3% THC, but this has gradually climbed up to over 10% by 2010, and 20-25% by 2025. A typical “joint” in the 1960s would have provided only about 5 mg, or one standard unit, of THC (the actual total THC in the joint was much higher, but only a fraction of this gets absorbed). Nowadays a similar-sized joint could lead to 40 mg THC absorption (or 8 standard units). These numbers once again remain rough approximations, since absorption depends on various other factors. But the difference between joints in the 60s and joints of today can be thought of as roughly similar to the difference between barely finishing one beer, and chugging down a whole six-pack.
Pharmacology: the cannabinoid receptors and what they are for
Cannabis acts on a signalling system that has evolved in many organisms for hundreds of millions of years, called the endocannabinoid system. This system features two main types of receptors—CB1 and CB2—switches on the surface of cells which are activated when a cannabis-like molecule attaches to them. The brain produces substances (“endogenous cannabinoids”) such as anandamide and 2-AG, which naturally stimulate CB1 and CB2. There is a natural spike of anandamide levels just after waking in the morning, while another endogenous cannabinoid peaks in the afternoon. Sudden stress causes a drop in endogenous cannabinoids for about an hour, therefore increasing the stress response. Aerobic exercise, for around 30 minutes, causes an increase in endogenous cannabinoid activity, possibly contributing to the so-called “runner’s high.” Endogenous cannabinoid activity declines slowly with age, possibly contributing to increased inflammatory diseases. Sleep deprivation can cause a surge in endogenous cannabinoid activity the next day, possibly contributing to increased appetite.
The CB1 cannabinoid receptor is widely distributed throughout the brain, and is involved in fine-tuning neurotransmitter release. Stimulation of the receptor inhibits an inhibitory system, thus leading to an overall increase of neuron activity. But the situation is complicated and often unpredictable, best thought of as shifting the balance of synchrony among brain cells, and with the precise effects differing between one person and another. One person may relax and laugh, another may become panicky or paranoid. One hears new depth in music, while another may be trapped in repetitive thoughts.
CB1 receptors are minimally present in the respiratory centres of the brainstem, so there is very low risk of cannabis causing dangerous changes in breathing; in this sense, cannabinoids are much safer than opiates. But cannabis can be dangerous in other ways, such as causing accidents, impaired driving, falls, vomiting, panic, psychosis, and interactions with other substances.
The CB2 receptor is present in immune cells, and is thought to be involved in immune modulation. There is growing evidence for CB2 expression in microglia and in some neuronal cell bodies or dendrites, especially under inflammatory conditions.
Frequent, heavy use of cannabis causes modest desensitization and down-regulation of CB1 receptors, therefore leading to tolerance and likely interfering with the body’s natural cannabinoid regulation system. You are less likely to produce a natural endocannabinoid response to stress or exercise etc. if your system is regularly swamped by cannabis consumption.
Evidence of risk and harm
Animal Studies
Animal studies, involving rodents as well as primates, have shown that longer-term regular exposure to THC caused persisting dose-dependent abnormalities in memory, social behaviour, reward sensitivity, impulsivity, and motivation. There are also psychosis-like behavioural effects. The animal effects were most pronounced when the THC exposure occurred during the adolescent stage of development.
CBD is another compound found in cannabis, which does not cause intoxication. It has complex interactions with a variety of other receptor systems in the brain other than CB1 and CB2. Animal studies did show potential benefits of CBD, including anti-anxiety, antipsychotic, and anti-inflammatory effects.
Psychosis
Psychosis is a disorder of thinking and perception, in which people have delusions, paranoia, hallucinations, or severe disorganization of thought process. People experiencing psychosis often lack the insight to know that they are having symptoms—they may sincerely believe that their experiences are an accurate or even inspired representation of reality. For this reason, psychosis can be challenging to treat. Some psychotic experiences can last just hours or days, but in other cases psychosis can become a lifelong phenomenon, either present continuously or recurring in episodes for weeks or months at a time, severely disrupting relationships, work, and overall health.
There is a strong association between cannabis use and psychosis, including chronic psychotic disorders such as schizophrenia. But there is also substantial non-causal association: careful attempts to control for confounding factors, as well as genetic studies and Mendelian-randomization studies, show that people who are already more predisposed to psychosis are more likely to use cannabis. So many of the studies showing strong associations are leaving readers with an exaggerated estimate of causal risk.
The bottom line, after taking these confounding factors into account, is that cannabis use does actually increase psychosis risk, just not quite to the same degree that simple association studies imply.
A rough estimate is that regular cannabis use at least doubles the risk of developing a psychotic illness, and this risk is higher with more frequent use and with higher dosages of THC. Rare or sporadic low-dose recreational use carries a much lower risk, if any at all. For people who already have risk factors, such as a family or personal history of a psychotic illness, cannabis use clearly increases the likelihood and severity of psychotic episodes. For this reason, a safe recommendation would be for people with such risk factors to abstain from THC.
Cognition, IQ, dementia, and the adolescent brain
Cannabis acutely impairs cognition. The strongest and most consistent short-term effects are on attention, learning, memory, psychomotor performance, and aspects of executive control (reasoning, judgment, and self-regulation). Many claims about cognitive effects neglect to give us a clear idea about “how much” this change might be. To give a very rough estimate of the magnitude of the effect, you could think of THC intoxication generally leading to a reduction of one’s performance on a school test by about one letter grade. But of course, this is a rough estimate, and different individuals could be impacted in different ways.
There could be some exceptions, in which cannabis intoxication might relax inhibitions and lead to a more imaginative, enjoyable, or engaged participation with studying or learning. But there would need to be the greatest of care to balance this effect with other aspects of cognitive impairment.
Heavy lifetime cannabis use has been associated with altered brain activation during working-memory tasks, and many reviews conclude that frequent use, especially if early and sustained, is associated with worse cognitive performance, worse academic outcomes, and poorer executive functioning. There are non-causal associations (persons with other causes for their cognitive problems are more likely to use cannabis) but there is still convincing evidence that early-onset heavy cannabis use could lead to small but significant persisting reductions in IQ.
For young people, the simplest harm-reduction advice is to delay initiation as long as possible; avoid frequent use; avoid high-potency THC; and do not use cannabis as the main way to manage anxiety, sleep, loneliness, boredom, ADHD, or depression.
Mood Symptoms
Adolescent cannabis use is associated with later depressive symptoms. Once again, there could be a great deal of non-causal association here. But for a young person already struggling with depression, social isolation, trauma, or suicidal thoughts, cannabis can easily become part of a worsening cycle: short-term relief, followed by poorer sleep, poorer motivation, more avoidance, more dysregulation, and a deeper dependency on intoxication as a coping strategy.
ADHD & Motivation
Some people with ADHD say cannabis helps them slow down, feel less restless, sleep more easily, or feel less emotionally jagged. People with ADHD may also be more drawn to cannabis because of impulsivity, novelty seeking, frustration, poor sleep, chronic under-reward, or a wish to dampen overstimulation. But the better reviews do not support cannabis as a reliable treatment for ADHD. And many studies do not accurately measure THC dose, route, potency, frequency, or product type.
Motivation is harder to study, but the clinical pattern is familiar: some (though not all) regular users have lower drive, difficulty with persistence, procrastination, educational drift, and blunted ambition. This may be partly non-causal; perhaps some people with lower drive are simply more likely to use cannabis. But if someone already has ADHD, low motivation, academic problems, or difficulty having a regular daily structure, then cannabis is unlikely to be helpful. More often it seems to make disengagement feel more comfortable.
Physical risks: lungs, smoke, and vaping
Smoking cannabis is harmful to the lungs. It causes chronic bronchitis symptoms with airway inflammation.
Just like tobacco smoke, cannabis smoke contains particulates and tar. The smoke contains reactive oxygen species (which can cause inflammation and cellular damage), and polycyclic hydrocarbons such as benzo[a]pyrene (a cause of lung cancer). Some older work even suggested that marijuana joints could deposit more tar than tobacco cigarettes of comparable size because of deeper inhalation, longer breath holding, and lack of filtration. Therefore there is a cancer risk, but the evidence is not as robust compared to what we know about cancer risks from tobacco products.
Vaping is not a clean solution either. It may reduce some combustion products compared with smoking, but it delivers THC very efficiently, encourages high-potency use, and has its own toxicity problems. Vaping still exposes the lungs to aerosols, solvents, metals, and other uncertainties. Toxicity risk from vaping remains under-studied.
Cannabinoid hyperemesis syndrome
Cannabinoid hyperemesis syndrome is caused by prolonged, heavy cannabis use. The symptoms are recurrent nausea, abdominal pain, and frequent cycles of severe vomiting. It is not rare, but the diagnosis is often delayed after years of progressive symptoms, sometimes because it is assumed that cannabis should relieve nausea, so people continue or escalate their previous usage pattern.
The syndrome is not fully understood, but may be caused in part by disruption of the TRPV1 receptor system. TRPV1 (Transient Receptor Potential Vanilloid 1) receptors are responsible for the sensation of heat or pain. In the brain, they are involved in other functions including the feeling of nausea, and also in learning, memory, and reward. Stimulation of these receptors at first causes pain or nausea, but eventually they become desensitized, which is why stimulating agents such as capsaicin (the “hot” ingredient in hot peppers) cause burning at first, but then can cause pain relief with sustained use. Cannabinoids can relieve nausea by interacting with TRPV1 receptors, but it is possible that high-dose THC over a long period of time simply overwhelms the stability of this system, leading to severe nausea.
The main treatment for this syndrome is cessation of THC use. Anti-nauseant medication often does not work very well. Interestingly, people with this problem often get temporary relief by having hot showers, probably because the heat triggers TRPV1 receptors. Similarly, topical capsaicin cream (which also triggers TRPV1) applied to a small area of the abdomen, can sometimes help.
Driving and workplace safety
Cannabis intoxication makes driving more dangerous. Driving simulation studies in which participants smoked cannabis show impairment for hours after smoking. The impairment pattern includes slowed reaction time, worse divided attention, poorer lane control, and poorer judgment. One study of driving performance in regular users suggested resolution of impairment by around 4.5 hours in most participants, but this should not be taken as a universal safe interval. In studies, people often felt they were ready to drive safely before their actual driving performance had recovered. The combination of cannabis with alcohol is especially dangerous.
Cannabis use is also particularly dangerous on job sites, particularly involving industrial equipment or other safety-sensitive tasks. Most of the evidence shows a clear safety hazard if cannabis is ingested before or during a work shift, while risk is much less if cannabis is used after hours—but even then, sleep, dose, edibles, and residual impairment are relevant factors, which could cause more prolonged impairment than average.
THC has a complicated metabolism, such that most of the immediate effects wear off after 4-6 hours or so (shorter for smoking or vaping, longer for edibles especially when consumed with a fatty meal), but there is residual THC that stays in the body at a lower level for a much longer time. So drug testing simply showing the presence of THC is not a reliable indicator of impairment, and drug levels do not correlate very well with impairment levels.
Generally speaking, one unit (5 mg) of THC could be compared to 1-2 standard drinks, in terms of capacity to impair driving (this is my own very rough estimate based on my review of the evidence). This impairment could last for at least 4.5 hours after ingestion. There is a lot of variability here, depending on individual sensitivities and other factors, so this comparison should not be considered a strict guideline. I mention this to at least introduce some type of “anchor” in a situation where many people have no idea how much they are using. It would be like being offered a drink at a bar, but having no idea of how much alcohol is actually present.
The bottom line is to beware of impairment due to cannabis use, and avoid all safety-sensitive tasks if you have any signs of intoxication. One should not drive within at least 6 hours of using cannabis, and even after 6 hours one must be sure there is no residual impairment. This is not a guarantee of safety—it is a minimum caution. With edibles, high doses, alcohol, or unusual sensitivity, the interval may need to be much longer.
Evidence of benefits and therapeutic uses
There are some real therapeutic roles for cannabinoids, but they are limited.
Purified prescription CBD can be used to treat several particular types of severe epilepsy, at doses much higher than those commonly found in consumer products (for example 300 mg several times per day). There are various side effect problems which must be monitored, such as fatigue, liver enzyme elevation, and diarrhea.
Cannabinoid-based products can be effective to treat chemotherapy-induced nausea and vomiting, especially when standard treatment is inadequate.
Cannabinoids can help relieve spasticity (painful muscle cramps) in multiple sclerosis.
THC and CBD products are often touted as a treatment for chronic pain syndromes. Animal studies generally support the idea that THC can improve inflammatory or neuropathic pain. But review studies looking at use in humans show that there is only slight improvement in pain, with very little functional improvement, but with considerably more dizziness, sedation, and nausea. The evidence is strongest for treating neuropathic pain, but the expectation should be of very modest or short-term benefits. CBD alone is not associated with improved pain or function.
Cannabis (particularly a THC:CBD combo) has one genuinely encouraging modern randomized controlled trial for acute migraine, but there is still a lack of convincing long-term controlled evidence as a daily preventative treatment. The dose used in this study was approximately one standard unit or less of vaporized THC--while many cannabis users are taking much more than that, or are not even sure how much they are taking. In any case, long-term use carries a risk for causing tolerance, medication overuse headaches, dependency, sedation, hyperemesis syndrome, psychiatric destabilization, and cognitive problems.
For mental disorders and substance use disorders, the evidence is thinner still. A 2026 Lancet Psychiatry meta-analysis found no benefit of cannabinoids for anxiety disorders, anorexia nervosa, psychotic disorders, post-traumatic stress disorder, and several substance-use outcomes, while adverse events were more common. There is some evidence of usefulness in Tourette’s Syndrome, autism traits, and insomnia, but better-quality research is needed.
CBD remains more plausible, and generally less harmful, than THC. It is less intoxicating, less likely to provoke psychosis, and more pharmacologically attractive as a medicine. But once one leaves epilepsy and a few other narrow domains, the evidence becomes much thinner very quickly. As for the newer minor cannabinoids—CBG, CBN, CBC, THCV, and the rest—they are pharmacologically interesting, but at present their marketing is far ahead of their proof.
It should be noted that research showing CBD as an effective medical treatment for various conditions involved doses of at least 300 mg per day, and often much more. But commercial CBD products often contain only a tiny fraction of this, such as 30-50 mg; such low doses have not shown any benefit in controlled studies.
Treatment of intoxication and cannabis use disorder
Acute cannabis intoxication is usually treated supportively: quiet setting, reassurance, low stimulation, hydration, and assessment for other substances or other causes of agitation or confusion. Severe panic, agitation, or psychotic symptoms may require short-term benzodiazepines or antipsychotics, depending on the situation. Hyperemesis is its own special problem, discussed above.
For cannabis use disorder, the most evidence-based treatments remain psychosocial: cognitive behavioural therapy, motivational enhancement, and contingency management. There is still no approved pharmacotherapy that clearly and reliably treats cannabis dependence. The naltrexone literature is interesting, but mixed. There is human laboratory evidence that naltrexone maintenance can reduce cannabis self-administration and reduce some of the positive subjective effects, but that is not the same thing as showing robust real-world treatment success in treatment-seeking patients. So I would describe naltrexone as an interesting lead, not a standard treatment.
Social policy and the problem of too many shops
There are over 3,000 cannabis retail businesses in Canada. Sales have risen sharply over the years, with current annual revenue of over $5 billion in Canada.
I support the civil-liberties argument for decriminalization and legalization. But I don’t think the proliferation of cannabis shops is good for the community, given the many social harms of heavy use. Also I wonder about the opportunity cost: think of all the other interesting shops or restaurants we could have in our neighbourhoods, instead of even more cannabis or vape shops.
Conclusions
In conclusion, I think cannabis use could be viewed as an enjoyable recreational activity. It could be relaxing, soften social tension, and give ordinary experience a pleasant strangeness. For some people it could relax inhibitions, allow different perspectives of thinking, or increase enjoyment of other activities (such as music or even academic work). For some people, it could be a sincere delight, part of a meaningful lifestyle, a joy of life. And it could be argued that overall, cannabis use in society is less harmful than alcohol use.
But there are substantial risks of harm, especially when it is used frequently or in high doses. The potency of cannabis products has increased greatly over the years, and it can be hard to know how much you are taking. Many people are ingesting doses that are roughly comparable to binge drinking a six-pack of beer or a whole bottle of wine. If cannabis is to be used more safely, the dose should be regulated in the same way that one would consume alcohol safely: a maximum of 1-3 standard doses (5-15 mg THC) per 24 hours, no more than a few times per month. People should avoid cannabis entirely if they have significant mental health risks, especially a personal or family history of psychosis.
Acute intoxication makes driving or safety-sensitive work much more dangerous, so one should never drive within 6 hours of using cannabis, and even after 6 hours be sure that you are not still intoxicated. Frequent use poses other risks to health, including lung damage, long-term cognitive problems, and sometimes gastrointestinal problems. Sometimes cannabis can help treat medical symptoms such as neuropathic pain or migraine, but the benefits are likely very modest, and safest only for short-term use except for particular medically supervised situations, such as treating spasticity in multiple sclerosis.
Cannabis use should definitely not be marketed to children, since the risks of harm are greatest in people under 18. There should be changes to regulations to reduce the community presence, marketing, and impact of the cannabis retail industry. Legalization is better than prohibition, but legalization should not not let us lose sight of public health, safety, and social policy.
Selected annotated bibliography
Ren, G., Zhang, X., Li, Y., Ridout, K., Serrano-Serrano, M. L., Yang, Y.,
Liu, A., Ravikanth, G., Nawaz, M. A., Mumtaz, A. S., Salamin, N., Fumagalli,
L., & Sun, Y. (2021). Large-scale whole-genome resequencing unravels the
domestication history of Cannabis sativa. Science Advances, 7(29),
eabg2286. doi:10.1126/sciadv.abg2286
This is one of the best sources for cannabis domestication. Its strength
is genomic breadth rather than folklore or older botanical speculation.
Ren, M., Tang, Z., Wu, X., Spengler, R., Jiang, H., Yang, Y., &
Boivin, N. (2019). The origins of cannabis smoking: Chemical residue evidence
from the first millennium BCE in the Pamirs. Science Advances, 5(6),
eaaw1391. doi:10.1126/sciadv.aaw1391
This is the key archaeological paper for early psychoactive cannabis
smoking. It does not prove the first human use of cannabis overall, but it
provides strong chemical evidence for high-THC cannabis being burned in ritual
contexts around 500 BCE.
Duvall, C. S. (2019). A brief agricultural history of cannabis in Africa,
from prehistory to canna-colony. EchoGĂ©o, 48. doi:10.4000/echogeo.17599
Duvall is useful because he corrects the common neglect of Africa in
cannabis history. He emphasizes that cannabis was incorporated into African
smoking cultures and that African innovation helped shape global cannabis
smoking.
Freeman, T. P., & Lorenzetti, V. (2020). “Standard THC units”: A
proposal to standardize dose across all cannabis products and methods of
administration. Addiction, 115(7), 1207–1216. doi:10.1111/add.14842
This is the source to cite for the 5 mg standard THC unit. It is useful
for public health communication and research comparison. It should not be
interpreted as saying that 5 mg is safe, benign, or an appropriate serving for
everyone.
ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., &
Church, J. C. (2016). Changes in cannabis potency over the last two decades,
1995–2014: Analysis of current data in the United States. Biological
Psychiatry, 79(7), 613–619. doi:10.1016/j.biopsych.2016.01.004
This is a foundational potency-monitoring paper. It supports the claim
that cannabis potency has increased substantially over recent decades. Its
limitation is that it uses U.S. seizure data, which may not perfectly represent
all legal-market products.
Health Canada. (2026). Canadian Cannabis Survey 2024: Summary.
Government of Canada.
This is the most useful Canadian source for current general-population
cannabis use. It gives the contemporary prevalence figures and helps avoid
relying on outdated pre-legalization estimates.
Health Canada. (2025). Alcohol and drug use among students in Canada,
2023–24. Government of Canada.
This is the best source for Canadian grade 7–12 cannabis use. It supports
the figures on past-year student use and frequent use.
Statistics Canada. (2026). Canada’s cannabis business since
legalization. Statistics Canada.
This source supports the policy section on sales, retail growth, and
government revenue. It is useful because it makes clear that cannabis is not
merely a private choice but a large commercial sector with public-revenue
implications.
Friesen, E. L., Konikoff, L., Dickson, S., & Myran, D. T. (2024).
Geographic clustering of cannabis stores in Canadian cities: A spatial analysis
of the legal cannabis market 4 years post-legalisation. Drug and Alcohol
Review. doi:10.1111/dar.13869
It quantifies retail clustering rather than leaving the argument at the
level of personal irritation. Its findings support concern about store density
and neighbourhood-level normalization.
National Academies of Sciences, Engineering, and Medicine. (2017). The
health effects of cannabis and cannabinoids: The current state of evidence and
recommendations for research. National Academies Press. doi:10.17226/24625
This remains the single best broad evidence synthesis. It is useful for
therapeutic effects, acute cognition, respiratory effects, and many risk
domains. Its limitation is age: the legal-market landscape has changed
substantially since 2017, especially potency and vaping.
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E.
(2016). Meta-analysis of the association between the level of cannabis use and
risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269.
doi:10.1093/schbul/sbw003
This remains one of the best dose-response summaries for cannabis and
psychosis. Its great strength is not merely showing association, but showing
that heavier use is associated with greater risk. The limitation is that
observational studies cannot fully eliminate confounding.
Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson,
C., Quigley, H., Rodriguez, V., Jongsma, H. E., Ferraro, L., La Cascia, C., La
Barbera, D., Tarricone, I., Berardi, D., Szöke, A., Arango, C., Tortelli, A.,
Velthorst, E., Bernardo, M., Del-Ben, C. M., Menezes, P. R., Selten, J.-P.,
Jones, P. B., Kirkbride, J. B., Rutten, B. P. F., de Haan, L., Sham, P. C., van
Os, J., Lewis, C. M., Lynskey, M., Morgan, C., & Murray, R. M. (2019). The
contribution of cannabis use to variation in the incidence of psychotic
disorder across Europe: The EU-GEI multicentre case-control study. The
Lancet Psychiatry, 6(5), 427–436. doi:10.1016/S2215-0366(19)30048-3
This is one of the most clinically useful psychosis studies because it
focuses on daily use and high-potency cannabis. It is vulnerable to the usual
case-control limitations, but it is very important for showing why potency and
frequency are important.
Hindley, G., Beck, K., Borgan, F., Ginestet, C. E., McCutcheon, R.,
Kleinloog, D., Ganesh, S., Radhakrishnan, R., D’Souza, D. C., & Howes, O.
D. (2020). Psychiatric symptoms caused by cannabis constituents: A systematic
review and meta-analysis. The Lancet Psychiatry, 7(4), 344–353.
doi:10.1016/S2215-0366(20)30074-2
This paper is important because it is not merely observational. It
reviews controlled human studies showing that THC can directly induce psychotic
and other psychiatric symptoms. It does not prove chronic schizophrenia
causation, but it strongly supports the psychotogenic potential of THC.
Murrie, B., Lappin, J., Large, M., & Sara, G. (2020). Transition of
substance-induced, brief, and atypical psychoses to schizophrenia: A systematic
review and meta-analysis. Schizophrenia Bulletin, 46(3), 505–516.
doi:10.1093/schbul/sbz102
This is the paper to cite when arguing that cannabis-induced psychosis
should not be dismissed as “just temporary.” Substance-induced psychoses,
particularly cannabis-related cases, can transition to longer-term psychotic
disorders. The limitation is heterogeneity across studies and diagnostic
categories.
Myran, D. T., Pugliese, M., Tanuseputro, P., Cantor, N., Rhodes, E.,
& Taljaard, M. (2025). Incident schizophrenia and cannabis use disorder
after cannabis legalization. JAMA Network Open, 8(2), e2457868.
This Ontario cohort study is important because it links cannabis use
disorder, policy liberalization, and incident schizophrenia diagnoses in a
large population. It does not prove that legalization alone caused
schizophrenia increases, but it highlights why public-health monitoring is
necessary.
Gobbi, G., Atkin, T., Zytynski, T., Wang, S., Askari, S., Boruff, J.,
Ware, M., Marmorstein, N., Cipriani, A., Dendukuri, N., & Mayo, N. (2019).
Association of cannabis use in adolescence and risk of depression, anxiety, and
suicidality in young adulthood: A systematic review and meta-analysis. JAMA
Psychiatry, 76(4), 426–434. doi:10.1001/jamapsychiatry.2018.4500
This is one of the best summary papers for adolescent mental-health
outcomes. It does not settle causality, but it is important because it counters
the cultural tendency to trivialize adolescent cannabis exposure.
Meier, M. H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R.
S. E., McDonald, K., Ward, A., Poulton, R., & Moffitt, T. E. (2012).
Persistent cannabis users show neuropsychological decline from childhood to
midlife. Proceedings of the National Academy of Sciences, 109(40),
E2657–E2664. doi:10.1073/pnas.1206820109
This is the famous longitudinal IQ-decline study. Its strength is the
pre-exposure cognitive measurement and long follow-up. Its limitation is that
later genetically informed studies suggest more confounding than the original
interpretation allowed.
Jackson, N. J., Isen, J. D., Khoddam, R., Irons, D., Tuvblad, C., Iacono,
W. G., McGue, M., Raine, A., & Baker, L. A. (2016). Impact of adolescent
marijuana use on intelligence: Results from two longitudinal twin studies. Proceedings
of the National Academy of Sciences, 113(5), E500–E508.
doi:10.1073/pnas.1516648113
This is an essential counterweight to overconfident IQ-causality claims.
The twin design controls for many familial confounders. It does not prove
cannabis is cognitively harmless, but it requires a cautious tone.
Power, E., Sabherwal, S., Healy, C., O’Neill, A., Cotter, D., &
Cannon, M. (2021). Intelligence quotient decline following frequent or
dependent cannabis use in youth: A systematic review and meta-analysis of
longitudinal studies. Psychological Medicine, advance online
publication, 1–7.
This meta-analysis sits between alarmism and dismissal. It suggests a
statistically significant but modest IQ effect in frequent or dependent youth
use, roughly around 2 IQ points on average.
Wade, N. E., et al. (2026). Longitudinal neurocognitive trajectories in a
large cohort of youth who use cannabis. Neuropsychopharmacology. Advance
online publication. doi:10.1038/s41386-026-02395-1
This is a current and important ABCD-study analysis. It supports concern
that adolescent cannabis use may alter neurocognitive trajectories,
particularly episodic memory with THC exposure. It is observational, so
residual confounding remains possible.
Verrico, C. D., Gu, H., Peterson, M. L., Sampson, A. R., & Lewis, D.
A. (2014). Repeated Δ9-tetrahydrocannabinol exposure in adolescent monkeys:
Persistent effects selective for spatial working memory. American Journal of
Psychiatry, 171(4), 416–425.
This is one of the most relevant animal studies because it uses
adolescent rhesus monkeys rather than rodents. It supports the adolescent
cognition concern. As always, primate findings are not identical to human
developmental outcomes, but they are unusually informative.
Li, Z., Mukherjee, D., Duric, B., et al. (2025). Systematic review and
meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on
schizophrenia-like behaviour in rodents. Molecular Psychiatry.
This is a useful synthesis of the rodent literature on adolescent
cannabinoid exposure and schizophrenia-like behaviours. It is valuable because
human randomized exposure studies would be unethical. The major limitation is
heterogeneity across animal models, cannabinoid compounds, doses, and
behavioural tests.
Hirvonen, J., Goodwin, R. S., Li, C.-T., Terry, G. E., Zoghbi, S. S.,
Morse, C., Pike, V. W., Volkow, N. D., Huestis, M. A., & Innis, R. B.
(2012). Reversible and regionally selective downregulation of brain cannabinoid
CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry, 17(6),
642–649.
This is a key receptor-adaptation paper. It shows that chronic daily
cannabis use changes CB1 receptor availability in the living human brain and
that at least some of these changes are reversible with abstinence
Francisco, A. P., Lethbridge, G., Patterson, B., et al. (2023). Cannabis
use in attention-deficit/hyperactivity disorder: A scoping review. Journal
of Psychiatric Research, 157. doi:10.1016/j.jpsychires.2022.11.029
This is the best source for the ADHD section. It acknowledges
self-reported benefit but finds that most studies show worsening or no effect.
It also highlights a major weakness in the literature: poor measurement of THC
and CBD exposure.
Skumlien, M., Mokrysz, C., Freeman, T. P., & Lawn, W. (2024). Is
cannabis use associated with motivation? A review of recent acute and non-acute
studies. Current Behavioral Neuroscience Reports, 11, 33–43.
doi:10.1007/s40473-023-00268-1
This is the best corrective against a simplistic “amotivational syndrome”
stereotype. It shows that the evidence is mixed and that the old caricature is
too crude. It still leaves room for acute motivational effects and impairment
associated with cannabis use disorder.
Chou, R., Ahmed, A. Y., Dana, T., Morasco, B. J., Bougatsos, C., Fu, R.,
& Williams, L. (2025). Living systematic review on cannabis and other
plant-based treatments for chronic pain: 2025 update. Agency for Healthcare
Research and Quality. doi:10.23970/AHRQEPCCER250UPDATE2025
This is one of the strongest and most practical sources for chronic pain.
Its central message is modest: some cannabinoid products may produce small
short-term pain improvements, especially in neuropathic pain, but adverse
effects are common and long-term evidence is weak.
Wilson, J., Dobson, O., Langcake, A., Mishra, P., Bryant, Z., Leung, J.,
Dawson, D., Graham, M., Teesson, M., Freeman, T. P., Hall, W., Chan, G. C. K.,
& Stockings, E. (2026). The efficacy and safety of cannabinoids for the
treatment of mental disorders and substance use disorders: A systematic review
and meta-analysis. The Lancet Psychiatry, 13(4), 304–315.
doi:10.1016/S2215-0366(26)00015-5
This is the strongest recent corrective against broad psychiatric claims
for cannabinoids. It shows little evidence of benefit for many common
psychiatric indications. It is especially important because the marketing and
clinical enthusiasm in this area have outrun the trial evidence.
Schuster, N. M., Wallace, M., Buse, D. C., Marcotte, T. D., et al.
(2025). Vaporized cannabis versus placebo for acute migraine: A randomized
controlled trial. Headache. Advance online publication.
doi:10.1111/head.70025
This is an important early trial for acute migraine. It supports cautious
interest, especially in THC/CBD combination products, but it is not enough to
make cannabis a standard migraine treatment. Long-term safety and
medication-overuse risk remain concerns.
Marcotte, T. D., Umlauf, A., Grelotti, D. J., Sones, E. G., Sobolesky, P.
M., Smith, B. E., Hoffman, M. A., Hubbard, J. A., Severson, J., Huestis, M. A.,
& Grant, I. (2022). Driving performance and cannabis users’ perception of
safety: A randomized clinical trial. JAMA Psychiatry, 79(3), 201–209.
doi:10.1001/jamapsychiatry.2021.4037
This is one of the most useful driving studies because it examines real
users after ad libitum smoking. The key clinical lesson is not merely that
impairment occurs, but that self-perceived recovery can precede objective
recovery.
Ruberto, A. J., Sivilotti, M. L. A., Forrester, S., et al. (2021).
Intravenous haloperidol versus ondansetron for cannabis hyperemesis syndrome:
The HaVOC randomized controlled trial. Annals of Emergency Medicine.
doi:10.1016/j.annemergmed.2020.08.021
This is one of the better acute-treatment trials for cannabinoid
hyperemesis syndrome. It supports haloperidol as a legitimate
emergency-treatment option. The trial is not huge, but it is much stronger
evidence than anecdote alone.
Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L.
(2016). Psychosocial interventions for cannabis use disorder. Cochrane
Database of Systematic Reviews, 2016(5), CD005336.
doi:10.1002/14651858.CD005336.pub4
This is the best concise source for cannabis-use-disorder treatment. It
supports psychosocial interventions such as CBT, motivational enhancement, and
contingency management. It also highlights the limits of treatment: benefits
are real but often modest, and relapse remains common.
This study supports acute migraine treatment with vaporized THC:CBD flower, not daily prophylaxis. The THC:CBD combination outperformed placebo on several meaningful 2-hour outcomes, while CBD alone did not. Its main limitation is duration: it does not answer questions about frequent use, tolerance, medication-overuse headache, dependence, or long-term cognitive/psychiatric effects.
Pini, L. A., Guerzoni, S., Cainazzo, M. M., et al. (2012). Nabilone for the treatment of medication-overuse headache: Results of a preliminary double-blind, active-controlled, randomized trial. The Journal of Headache and Pain, 13, 677–684.
This small RCT studied nabilone, a synthetic THC-like cannabinoid, in medication-overuse headache. It found benefit compared with ibuprofen on pain intensity, analgesic intake, dependence measures, and quality of life, but headache-day reduction was modest and the study was short. It is relevant mechanistically, but it should not be mistaken for proof that botanical cannabis prevents chronic migraine.
Okusanya, B. O., Lott, B. E., Ehiri, J., McClelland, J., & Rosales, C. (2022). Medical cannabis for the treatment of migraine in adults: A review of the evidence. Frontiers in Neurology, 13, 871187. doi:10.3389/fneur.2022.871187
This is the best migraine-specific systematic review. It is useful because it gathers the small and heterogeneous literature in one place. Its own conclusions are appropriately cautious: the evidence is promising, but high-quality trials are lacking. It also highlights the two most important safety concerns: tolerance and medication-overuse headache.
Kuruvilla, D. E. (2025). Cannabinoids in headache: Helpful or harmful? Current Opinion in Neurology, 38(5), 387–392.
This recent clinical review is useful because it frames the question exactly as it should be framed: cannabinoids may help some headache patients, but the unresolved safety and long-term-efficacy questions are substantial. It is especially relevant to the tension between patient-reported benefit and absence of long-term controlled data.
